Plain-English translation of NCT06868849 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called JMT203 to help patients with cancer cachexia—a serious condition where cancer causes significant, unintended weight loss and muscle wasting. The study has two parts: first, researchers will find the safest dose of the medication, and then they will test whether specific doses actually help patients gain weight and feel stronger compared to placebo (a dummy pill). The trial includes patients with colorectal cancer, pancreatic cancer, and other solid tumors.
Cancer cachexia is a devastating side effect that weakens patients and makes it harder to fight their cancer. Currently, there are limited treatment options for this condition, so this medication is being tested to see if it can help patients maintain their weight and muscle mass during cancer treatment.
You likely qualify if…
You likely don't qualify if…
In the first part of the study, you will receive gradually increasing doses of the medication to find the safest amount. In the second part, you will be randomly assigned to receive either the medication (at one of two doses) or a placebo, along with your regular cancer treatment, for 12 weeks. You will visit the clinic regularly for check-ups, blood tests, and weight measurements to see if the medication is helping you regain weight and feel stronger.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shanghai JMT-Bio Inc.
Enrollment target
~307 participants
Started
May 2024
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Trials Information Group Officer
Shanghai JMT-Bio Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.